Investors & media > Press releases

These are PDFs. To view these you need Adobe Reader which can be downloaded from Adobe.com.

15/04/08 Piramed acquired by Roche
17/03/08 Piramed Announces Progress in its Collaboration with Genentech to develop a new class of Anti-Cancer Drugs
09/07/07 Piramed Pharma wins Innovation in Drug Discovery & Development Award
28/03/07 Piramed presented at BioTrinity 2007, as one of the "most promising companies" View presentation here
01/05/06 Piramed’s Professor Peter Parker elected to the Fellowship of the Royal Society
11/04/06 FierceBiotech honors Piramed as one of the "Fierce 15" Biotech Companies of 2006
30/11/05 Piramed signs Collaboration with Genentech to develop new class of anti-cancer drugs
03/05/05 Piramed appoints David Knowles as Chief Scientific Officer and R&D Director
17/06/04 Piramed strengthens its board with the appointment of Ian Kent as non executive Chairman and Frank Fildes as non executive director
19/05/04 Collaboration with the Institute of Cancer Research to advance new class of anti-cancer agent into the clinic
01/09/03 Piramed announces the appointment of Dr. Michael Moore as CEO
09/07/03 JPMorgan Partners and Merlin Biosciences Lead £8 ($13.2) Million Series A Investment in PIRAMED